Several human pathogens exploit the kinetic forces generated by polymerizing actin to power their intracellular motility. Human cell-autonomous immune responses activate ...

Now, in a new paper in the journal Cell, researchers say they've done just that, thanks in large part to the antibodies that Friede has developed over nearly a quarter century of self-envenomation.

--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

For hematologic cancers, the past decade was marked by the rise of alternative immunotherapies such as antibody-drug conjugates (ADCs), bispecific antibodies that engage T cells (BsAbs), and chimeric ...